Ophthotech Corporation Reports Second Quarter 2016 Financial And Operating Results
NEW YORK--(BUSINESS WIRE)--Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the second quarter ended June 30, 2016 and provided an update on the Company’s business and product development programs.
“During the second quarter, we reached a significant milestone in our Fovista® program as we completed patient recruitment in our third Phase 3 trial of Fovista® in combination with Eylea® or Avastin®,” said David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board of Ophthotech. “We look forward to providing initial, topline data from our two pivotal Phase 3 trials of Fovista® in combination with Lucentis® in the fourth quarter of this year.”
“During the second quarter, we reached a significant milestone in our Fovista® program as we completed patient recruitment in our third Phase 3 trial of Fovista® in combination with Eylea® or Avastin®,” said David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board of Ophthotech. “We look forward to providing initial, topline data from our two pivotal Phase 3 trials of Fovista® in combination with Lucentis® in the fourth quarter of this year.”